Another study performed a pooled analysis of 1961 advanced HER2-positive BC cases treated with T-DM1 to determine the incidence of cardiotoxicity, its clinical presentation, and possible risk factors related to T-DM1-associated cardiotoxicity. Here, ERBB2 is linked to breast cancer.